EUVIMEDEUVIMED entdecken
Crossref

Ailanthone targets the EGR3-SOCS2 regulatory pathway to suppress vasculogenic mimicry in prostate cancer

Hong Pan, Shuyi Chen, Shanming Ruan, Jiamin Lu, Kai Zhang

Biochemical Pharmacology · 2026-08 · 250 · 117982

DOI: 10.1016/j.bcp.2026.117982 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biochemical Pharmacology, 2026-08. Verfasst von Hong Pan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hang…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Suppressor of Cytokine Signaling Proteins, Early Growth Response Protein 3, Neovascularization, Pathologic. Die Arbeit nennt 57 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostate cancer (PCa) frequently progresses to castration-resistant stages with poor prognosis, in which vasculogenic mimicry (VM) contributes to tumor aggressiveness and therapeutic resistance. Here, we investigated the antitumor effects of the natural quassinoid Ailanthone (AIL) and its impact on VM in PCa. Our study demonstrates that AIL markedly suppresses PCa cell viability, induces apoptosis and G1/S cell-cycle arrest, and inhibits migration, invasion, stemness, and VM formation. Mechanistically, AIL enhances early growth response protein 3 (EGR3) binding to the promoter of suppressor of cytokine signaling 2 (SOCS2), leading to SOCS2 upregulation and subsequent inhibition of JAK/STAT3 signaling. Functional rescue experiments reveal that SOCS2 or EGR3 silencing partially reverses the inhibitory effects of AIL on malignant phenotypes and VM. In vivo, AIL significantly reduces tumor growth, promotes apoptosis, and attenuates VM formation, effects that are weakened upon SOCS2 knockdown. Collectively, these findings indicate that AIL exerts potent anti-tumor and anti-VM activities in PCa by activating the EGR3-SOCS2 axis and suppressing JAK/STAT3 signaling, highlighting its potential as a promising therapeutic strategy for advanced and treatment-resistant PCa.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsSuppressor of Cytokine Signaling ProteinsEarly Growth Response Protein 3Neovascularization, PathologicMaleHumansAnimalsSignal TransductionCell Line, TumorMice, NudeMiceApoptosisMice, Inbred BALB C

Stichwörter der Autor:innen

AilanthoneJAK/STAT3 signaling pathwayProstate cancerSOCS2Vasculogenic mimicry

Substanzen

Suppressor of Cytokine Signaling ProteinsSOCS2 protein, humanEarly Growth Response Protein 3

Autor:innen und Institutionen

  • Department of Oncology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou 310006, Zhejiang, China.
  • Department of Oncology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou 310006, Zhejiang, China. Electronic address: zhangkaitcm@zcmu.edu…

Zitieren

APA

Pan, H., Chen, S., Ruan, S., Lu, J., & Zhang, K. (2026). Ailanthone targets the EGR3-SOCS2 regulatory pathway to suppress vasculogenic mimicry in prostate cancer. Biochemical Pharmacology, 250, 117982. https://doi.org/10.1016/j.bcp.2026.117982

Vancouver

Pan H, Chen S, Ruan S, Lu J, Zhang K. Ailanthone targets the EGR3-SOCS2 regulatory pathway to suppress vasculogenic mimicry in prostate cancer. Biochemical Pharmacology. 2026;250:117982. doi:10.1016/j.bcp.2026.117982

BibTeX
@article{Pan2026,
  author = {Pan, Hong and Chen, Shuyi and Ruan, Shanming and Lu, Jiamin and Zhang, Kai},
  title = {Ailanthone targets the EGR3-SOCS2 regulatory pathway to suppress vasculogenic mimicry in prostate cancer},
  journal = {Biochemical Pharmacology},
  year = {2026},
  volume = {250},
  pages = {117982},
  doi = {10.1016/j.bcp.2026.117982}
}
Kostenlos starten →